A novel combinatorial approach using androgen receptor-targeted agents for treatment of prostate cancer

被引：0
|
作者：
Butler, Lisa [1 ]
Centenera, Margaret [1 ]
Marrocco, Deborah [1 ]
Carter, Sarah [1 ]
Bianco-Miotto, Tina [1 ]
Tilley, Wayne [1 ]
机构：
[1] Univ Adelaide, Adelaide, SA, Australia
来源：
CANCER RESEARCH | 2009年 / 69卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2399
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Sequence of androgen receptor-targeted vaccination with androgen deprivation therapy affects anti-prostate tumor efficacy
    Muralidhar, Anusha
    Gamat-Huber, Melissa
    Vakkalanka, Sita
    McNeel, Douglas G.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2024, 12 (05)
  • [42] Estrogen Receptor-Targeted and Progesterone Receptor-Targeted PET for Patients with Breast Cancer
    Ulaner, Gary A.
    Fowler, Amy M.
    Clark, Amy S.
    Linden, Hannah
    PET CLINICS, 2023, 18 (04) : 531 - 542
  • [43] Quality of life for androgen receptor targeted agents in patients with metastatic castration resistant prostate cancer
    Kuzma, Monika
    Nekvindova, Lucie
    Kliment, Jan
    BRATISLAVA MEDICAL JOURNAL-BRATISLAVSKE LEKARSKE LISTY, 2024, 125 (09): : 572 - 579
  • [44] A Novel Recombinant Fcγ Receptor-Targeted Survivin Combines with Chemotherapy for Efficient Cancer Treatment
    Wu, Chiao-Chieh
    Chiang, Chen-Yi
    Liu, Shih-Jen
    Chen, Hsin-Wei
    BIOMEDICINES, 2021, 9 (07)
  • [45] Stereotactic ablative radiotherapy in castration-resistant prostate cancer patients with oligoprogression during androgen receptor-targeted therapy
    Ingrosso, G.
    Detti, B.
    Fodor, A.
    Caini, S.
    Borghesi, S.
    Triggiani, L.
    Trippa, F.
    Russo, D.
    Bruni, A.
    Francolini, G.
    Lancia, A.
    Marinelli, L.
    Di Muzio, N.
    Livi, L.
    Magrini, S. M.
    Maranzano, E.
    Musio, D.
    Aristei, C.
    Valeriani, M.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2021, 23 (08): : 1577 - 1584
  • [46] Stereotactic ablative radiotherapy in castration-resistant prostate cancer patients with oligoprogression during androgen receptor-targeted therapy
    G. Ingrosso
    B. Detti
    A. Fodor
    S. Caini
    S. Borghesi
    L. Triggiani
    F. Trippa
    D. Russo
    A. Bruni
    G. Francolini
    A. Lancia
    L. Marinelli
    N. Di Muzio
    L. Livi
    S. M. Magrini
    E. Maranzano
    D. Musio
    C. Aristei
    M. Valeriani
    Clinical and Translational Oncology, 2021, 23 : 1577 - 1584
  • [47] Novel targeted pro-apoptotic agents for the treatment of prostate cancer
    Huang, Xu
    Zhang, Xiaoping
    Farahvash, Benyamin
    Olumi, Aria F.
    JOURNAL OF UROLOGY, 2007, 178 (05): : 1846 - 1854
  • [48] Predictive factors for effectiveness from novel androgen-receptor-axis-targeted agents in patients with metastatic prostate cancer.
    Nishimoto, Koshiro
    Nakajima, Kenichi
    Oyama, Masafumi
    Kaneko, Go
    Takahashi, Satoru
    Matsuyama, Hideyasu
    Shiina, Hiroaki
    Ichikawa, Tomohiko
    Horikoshi, Hiroyuki
    Hashine, Katsuyoshi
    Sugiyama, Yutaka
    Miyao, Takeshi
    Kamiyama, Manabu
    Harada, Kenichi
    Ito, Akito
    Mizokami, Atsushi
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [49] Fc receptor-targeted therapies for the treatment of inflammation, cancer and beyond
    P. Mark Hogarth
    Geoffrey A. Pietersz
    Nature Reviews Drug Discovery, 2012, 11 : 311 - 331
  • [50] Fc receptor-targeted therapies for the treatment of inflammation, cancer and beyond
    Hogarth, P. Mark
    Pietersz, Geoffrey A.
    NATURE REVIEWS DRUG DISCOVERY, 2012, 11 (04) : 311 - U87
12345